Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply

被引：0
|
作者：
Ellis, Matthew J. [1 ]
Robertson, John F. R. [2 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Nottingham, Derby, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 16期
关键词：
FULVESTRANT; 500; MG; ANASTROZOLE; TRIAL; 1ST;
D O I：
10.1200/JCO.2016.66.6727
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1960 / +
页数：3
相关论文
共 50 条
  • [1] Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
    Reinert, Tomas
    Barrios, Carlos H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1959 - +
  • [2] A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy
    Polley, Mei-Yin C.
    Dickler, Maura N.
    Sinnwell, Jason
    Tenner, Kathleen
    de la Haba, Juan
    Loibl, Sibylle
    Goetz, Matthew P.
    Bergh, Jonas
    Roberston, John
    Couch, Fergus
    Ellis, Matthew J.
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 15 - 23
  • [3] Endocrine therapy leads the first- and second-line treatment options for hormone receptor-positive advanced breast cancer - comments on the Monarch plus study
    Wang, Xiaojia
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [4] Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer
    Connolly, Roisin M.
    Stearns, Vered
    ONCOLOGY-NEW YORK, 2013, 27 (06): : 571 - +
  • [5] First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study
    Di Leo, Angelo
    Jerusalem, Guy
    Torres, Roberto
    Verhoeven, Didier
    Pendergrass, Kelly
    Malorni, Luca
    Lichfield, Jasmine
    Martin, Miguel
    BREAST, 2018, 38 : 144 - 149
  • [6] Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
    Bian, Li
    Xu, Feng-Rui
    Jiang, Ze-Fei
    CHINESE MEDICAL JOURNAL, 2020, 133 (19) : 2338 - 2345
  • [7] Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer
    Ding, H.
    Fang, L.
    Xin, W.
    Tong, Y.
    Zhou, Q.
    Huang, P.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [8] Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer
    Tevaarwerk, Amye J.
    Wisinski, Kari B.
    O'Regan, Ruth M.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1148 - +
  • [9] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Shimoi, Tatsunori
    Sagara, Yasuaki
    Hara, Fumikata
    Toyama, Tatsuya
    Iwata, Hiroji
    BREAST CANCER, 2020, 27 (03) : 340 - 346
  • [10] Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy
    Chlebowski, Rowan T.
    CLINICAL BREAST CANCER, 2013, 13 (03) : 159 - 166
12345